MX2021014952A - Molecula de union especifica para cd73 y uso de la molecula de union. - Google Patents

Molecula de union especifica para cd73 y uso de la molecula de union.

Info

Publication number
MX2021014952A
MX2021014952A MX2021014952A MX2021014952A MX2021014952A MX 2021014952 A MX2021014952 A MX 2021014952A MX 2021014952 A MX2021014952 A MX 2021014952A MX 2021014952 A MX2021014952 A MX 2021014952A MX 2021014952 A MX2021014952 A MX 2021014952A
Authority
MX
Mexico
Prior art keywords
binding molecule
separate antibody
antigen binding
specific
binding part
Prior art date
Application number
MX2021014952A
Other languages
English (en)
Inventor
Wenlai Zhou
Qinghao Liu
Haiyan Yang
Hongling Wang
Original Assignee
Jacobio Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jacobio Pharmaceuticals Co Ltd filed Critical Jacobio Pharmaceuticals Co Ltd
Publication of MX2021014952A publication Critical patent/MX2021014952A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Una molécula de unión específica para CD73 y un uso de la molécula de unión; específicamente, se proporcionan un anticuerpo separado que se une a CD73 e inhibe la actividad de CD73 o una parte que se une al antígeno del anticuerpo separado, y un uso del anticuerpo separado o la parte que se une al antígeno del mismo en el tratamiento de enfermedades; también se proporcionan una molécula de ácido nucleico que codifica el anticuerpo separado o la parte que se une al antígeno del mismo, un vector de expresión para expresar el anticuerpo separado o la parte que se une al antígeno del mismo, una célula hospedera y un método de preparación.
MX2021014952A 2019-06-06 2020-06-05 Molecula de union especifica para cd73 y uso de la molecula de union. MX2021014952A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019090366 2019-06-06
PCT/CN2020/094489 WO2020244606A1 (zh) 2019-06-06 2020-06-05 对cd73具有特异性的结合分子及其用途

Publications (1)

Publication Number Publication Date
MX2021014952A true MX2021014952A (es) 2022-04-06

Family

ID=73653110

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014952A MX2021014952A (es) 2019-06-06 2020-06-05 Molecula de union especifica para cd73 y uso de la molecula de union.

Country Status (12)

Country Link
US (2) US11174319B2 (es)
EP (1) EP3981790A4 (es)
JP (1) JP2022535840A (es)
KR (1) KR20220016974A (es)
CN (1) CN113906051A (es)
AU (1) AU2020289179B2 (es)
BR (1) BR112021024553A2 (es)
CA (1) CA3142640A1 (es)
EA (1) EA202193351A1 (es)
MX (1) MX2021014952A (es)
TW (1) TWI790445B (es)
WO (1) WO2020244606A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
CN115991772B (zh) * 2022-08-12 2023-09-01 南京蓬勃生物科技有限公司 抗cd73抗体或其抗原片段及其应用
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101370830A (zh) * 2005-09-26 2009-02-18 米德列斯公司 抗cd70的人单克隆抗体
CN107074949B (zh) * 2014-08-07 2021-06-15 索隆-基特林癌症研究协会 抗神经酰胺抗体
BR112017006464A2 (pt) * 2014-10-10 2018-01-30 Innate Pharma bloqueio de cd73
MX2017006624A (es) * 2014-11-21 2017-08-21 Bristol Myers Squibb Co Anticuerpos contra cd73 y sus usos.
WO2017064043A1 (en) * 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
EP3387442A4 (en) * 2015-12-09 2019-05-08 Corvus Pharmaceuticals, Inc. HUMANIZED ANTI-CD73 ANTIBODIES
MY188386A (en) * 2017-01-24 2021-12-07 I Mab Biopharma Us Ltd Anti-cd73 antibodies and uses thereof
WO2018187512A1 (en) * 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
WO2018237157A1 (en) * 2017-06-22 2018-12-27 Novartis Ag CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF

Also Published As

Publication number Publication date
AU2020289179A1 (en) 2021-11-18
TWI790445B (zh) 2023-01-21
WO2020244606A1 (zh) 2020-12-10
AU2020289179B2 (en) 2024-05-02
CA3142640A1 (en) 2020-12-10
EA202193351A1 (ru) 2022-03-21
CN113906051A (zh) 2022-01-07
TW202112814A (zh) 2021-04-01
BR112021024553A2 (pt) 2022-05-24
JP2022535840A (ja) 2022-08-10
US20220064322A1 (en) 2022-03-03
US11174319B2 (en) 2021-11-16
US20210253730A1 (en) 2021-08-19
EP3981790A4 (en) 2023-10-11
EP3981790A1 (en) 2022-04-13
KR20220016974A (ko) 2022-02-10

Similar Documents

Publication Publication Date Title
MX2020004578A (es) Composiciones de casz y metodos de uso.
MX2021014952A (es) Molecula de union especifica para cd73 y uso de la molecula de union.
SG10201906762YA (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
WO2018191502A3 (en) Anti-cd137 antibodies and methods of use thereof
JOP20200313A1 (ar) أجسام مضادة dll3-cd3 ثنائية الخاصية
WO2007067991A3 (en) Human monoclonal antibodies to o8e
WO2016081748A3 (en) Antibodies against cd73 and uses thereof
EA201890796A1 (ru) Новое антитело к мезотелину и содержащая его композиция
WO2006089230A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
WO2007067730A3 (en) Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
WO2005097185A3 (en) Irta-5 antibodies and their uses
SG163554A1 (en) Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
PH12020551907A1 (en) Antagonizing cd73 antibody
WO2007038637A3 (en) Human monoclonal antibodies to cd70
NO20080362L (no) CD19-antistoffer og deres anvendelser
WO2008076560A3 (en) Human monoclonal antibodies to btla and methods of use
AU2019433019A8 (en) Antibodies binding CD40 and uses thereof
MY150246A (en) Alpha 5 - beta 1 antibodies and their uses
WO2020076977A3 (en) Dll3 single domain antibodies and therapeutic compositions thereof
BR112019005129A2 (pt) anticorpos anti-pd-1
ZA202201464B (en) Anti-tigit antibodies and application thereof
MX2021013913A (es) Composiciones y metodos para el tratamiento de enfermedades mediadas por atpasa.
WO2020070678A3 (en) Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
MX2021009975A (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer.
MX2020009550A (es) Proteinas de union a antigeno antagonistas.